Archive for the ‘research’ Category

Could Aspirin Have Cut COVID Deaths in Half?

The following is critical information especially for Lyme/MSIDS patients as these pathogens also cause hypercoagulation and metabolic issues.  Many patients have greatly benefitted from heparin as well as proteolytic enzymes as they both cut down fibrinogen, the proteins produced by the liver that help with blood clotting.  Unfortunately, too much fibrinogen causes “thick blood” making it even harder to treat pathogens.  Biofilm compounds this problem as well. The Japanese have demonstrated preventive antiviral effects against SARS-CoV-2 mutant strains and bovine herpes virus type 1 by using Nattokinase.  The mechanism appears to be proteolytic cleavage of viral proteins.

https://media.mercola.com/ImageServer/Public/2023/May/PDF/aspirin-for-covid-pdf.pdf

Could Aspirin Have Cut COVID Deaths in Half?

http://

Analysis by Dr. Joseph MercolaFact Checked

STORY AT-A-GLANCE

  • There was a massive discrediting propaganda campaign hurled at aspirin by Big Pharma fifty years ago when it came out with expensive and dangerous non-steroidal anti-inflammatories (NSAIDs)
  • Aspirin is a staple medicine that is frequently recommended as a remedy to control inflammation and prevent blood clots. It could have helped limit the pandemic death toll, had it not been downplayed and ignored
  • According to research published in April 2021, aspirin reduced COVID-19 patients’ need for mechanical ventilation by 44%, ICU admission by 43% and mortality by 47%
  • Proteolytic enzymes like lumbrokinase, serrapeptase and nattokinase are safer and perhaps even superior choices to aspirin for its anticlot properties. These enzymes, when taken on an empty stomach, act as natural anticoagulants by breaking down fibrin
  • Proteolytic enzymes may also be helpful for long-COVID. Researchers have found that people who die from COVID have extensive lung damage caused by persistent virus-infected cells that cause scar formation. Proteolytic enzymes can help dissolve this scar tissue, as fibrin is a primary component

Aspirin (acetylsalicylic acid) was introduced in 1899 as an alternative to sodium salicylate,1 a pain reliever and anti-inflammatory known for its unpleasant side effects such as stomach cramps, heartburn, nausea and vomiting. It’s been a staple medicine in most households ever since and is frequently recommended as a remedy to control inflammation and prevent blood clots that can lead to stroke and heart attack.

Aspirin also has other health benefits. It helps increase the oxidation of glucose as fuel for your body while inhibiting the release of fatty acids from your fat cells, specifically linoleic acid (LA), an omega-6 fat which I suspect is a primary driver of chronic disease.

This is important because nearly everyone in the U.S. has excessive LA in their tissues, as it takes seven years of a low LA diet to get it down to healthy levels. So, the last thing you want to do is increase the release of LA into your body from fat stores. It is far better to release LA slowly and allow your liver to process it. It is water soluble, so you can urinate it out without it being metabolized into inflammatory prostaglandins.

Importantly, aspirin will also lower your baseline cortisol — indirectly by lowering inflammation, and directly by inhibiting the enzyme 11-beta-hydroxysteroid dehydrogenase Type 1. This enzyme synthesizes active cortisol from the inactive precursor cortisone.

Aspirin lowers the production of stressed induced aldosterone, which can help to lower blood pressure. Aspirin increases your levels of carbon dioxide and progesterone while inhibiting the major inflammatory pathway, NF kappa-B, which will help your body naturally increase the synthesis of two powerfully important hormones that your body needs, testosterone and progesterone.

Aspirin also uncouples mitochondria. Uncoupling of mitochondrial oxidative metabolism from ATP production can help to increase your metabolic rate and help you lose weight. Dinitrophenol (DNP) is a drug that, like aspirin, uncouples mitochondrial metabolism and produces incredible weight loss. Sadly, it has a very low therapeutic index, so its effective dose is close to its toxic dose and is widely considered too dangerous for clinical use and is no longer available in the U.S.

Aspirin Reduced COVID-Related Hospital Deaths by 47%

Aspirin could also have helped limit the pandemic death toll, had it not been downplayed and overlooked. Many news outlets and COVID-specific websites warned against the use of aspirin for COVID infection, saying it could cause serious bleeding.

While bleeding is a potential side effect, aspirin is no riskier than other anticoagulants, such as heparin,2,3,4 which was recommended by the National Institutes of Health.5

According to research6 published in April 2021, aspirin significantly reduced COVID-19 patients’ need for mechanical ventilation, ICU admission and subsequent mortality. The retrospective, observational cohort study included patients admitted for COVID infection at multiple hospitals across the U.S. between March and July 2020. As reported by General Surgery News:7

“The study’s principal investigator, Jonathan Chow, MD, an assistant professor of anesthesiology and critical care medicine at George Washington University, in Washington, D.C., said:

‘At the beginning of the pandemic, in March and April of 2020, my colleagues and I observed that all these COVID patients in the intensive care unit began to develop excess clot formation and complications related to blood clots and microclot formation throughout the body.’

Numerous autopsy studies from last spring showed these patients had activation of platelets throughout the body and an excessive number of precursors to platelets, according to Dr. Chow.

‘That got us thinking, ‘Why don’t we start using an antiplatelet medication, such as aspirin, to treat these patients?’ he said. ‘Aspirin has been studied extensively in cardiovascular disease to prevent clot formation, and it is widely available and inexpensive.’”

Chow and his team reviewed the charts of 412 patients, 23.7% of whom had either received aspirin within 24 hours of admission, or had taken aspirin for at least seven days prior to admission, and 76.3% who did not.

After adjusting for several confounding variables, including comorbidities, aspirin was independently associated with a:

  • 44% decreased risk for mechanical ventilation
  • 43% reduced risk for ICU admission
  • 47% decrease in hospital mortality

Based on this research, it appears COVID-19-related hospital deaths could have been cut nearly in half, had aspirin been routinely used. Chow commented on the results:8

“The results of the study do not really surprise us because we know that COVID causes excess clot formation and we know that aspirin is a very potent blood thinner. So, when you have a disease that causes clots and a medication that thins your blood, that may lead to the protective effects that we found.”

Aberrant Coagulation in Severe Influenza Pneumonia

As in COVID-19, pneumonia caused by influenza also involves microclotting in the lungs. According to research published in 2016, aberrant coagulation is what causes a hyperinflammatory response in severe influenza pneumonia:9

“Dysfunctional coagulation is a common complication in pathogenic influenza, manifested by lung endothelial activation, vascular leak, disseminated intravascular coagulation and pulmonary microembolism.

Importantly, emerging evidence shows that an uncontrolled coagulation system, including both the cellular (endothelial cells and platelets) and protein (coagulation factors, anticoagulants and fibrinolysis proteases) components, contributes to the pathogenesis of influenza by augmenting viral replication and immune pathogenesis.”

This paper also highlighted the benefits of aspirin, noting it:10

  • Protects mice from lethal influenza virus infection
  • Acts as an anti-influenza virus agent in vitro by inhibiting pro-inflammatory NF-κB activity
  • Improves influenza outcomes
  • Potentially inhibits platelet activation

Fibrinolytics May Be the Key

According to the 2016 paper above, “Fibrinolysis is involved in both lung inflammation and the influenza A virus life cycle.” Fibrinolysis is a process that prevents blood clots from forming and growing. This is part of your body’s normal processes, but sometimes the clotting becomes too excessive, requiring a fibrinolytic to help break down the clots that have already formed.

Fibrin is the material that blood clots are made of, and while aspirin can help break them down, I believe proteolytic enzymes like lumbrokinase, serrapeptase and nattokinase are superior choices.

These enzymes, when taken on an empty stomach, away from food, act as natural anticoagulants by breaking down fibrin. They must be taken at least one hour before or two hours after meals containing protein, though. Otherwise, they’ll be wasted in the digestion of the protein in your food and won’t be able to activate their fibrinolytic properties.

Fibrinolytic Enzymes for COVID-19

Another paper11 published in July 2020, this one a case series, also hints at the usefulness of fibrinolytic enzymes for COVID. It presented three case studies of patients with severe COVID‐19 respiratory failure who were treated with tissue plasminogen activator (TPA), a serine protease enzyme found on endothelial cells that is involved in the breakdown of blood clots.12

All three patients benefited from the treatment, with partial pressure of oxygen/FiO2 (P/F) ratios, a measure of lung function, improving from 38% to 100%.

Other research13 has shown that the thrombolytic activity of equivalent amounts of nattokinase and TPA are identical, so nattokinase could be a useful alternative. The benefit of nattokinase is that you can take it at home, without a prescription, while TPA is an emergency stroke treatment that is only given intravenously to patients suspected of having an ischemic stroke.

Considering fibrinolytic enzymes are thrombolytics comparable to both aspirin14 and TPA, it seems reasonable to conclude that they can be helpful in the treatment of COVID-19.

Fibrinolytic Enzymes May Be Useful in Long-COVID as Well

Another paper15 published in November 2020 highlighted that people who died from COVID-19 had extensive lung damage, including clotting and long-term persistence of virus cells in pneumocytes and endothelial cells.

The findings indicate that virus-infected cells may persist for long periods inside the lungs, contributing to scar tissue. In an interview with Reuters,16 study co-author Mauro Giacca, a professor at King’s College London, described “really vast destruction of the architecture of the lungs,” with healthy tissue “almost completely substituted by scar tissue.”

This scar tissue, Giacca said, may be responsible for so-called “long COVID,” in which symptoms persist for months after the infection has cleared up. “It could very well be envisaged that one of the reasons why there are cases of long COVID is because there is vast destruction of lung (tissue),” he told Reuters. “Even if someone recovers from COVID, the damage that is done could be massive.”

The good news is that proteolytic enzymes can help dissolve scar tissue as well, as fibrin is a primary component. I would alternate between lumbrokinase and serrapeptase, as you’ll need to take it for about three months and sensitivity can develop over time if you use any one of them daily without interruption.

A Breakdown of the Top Three Fibrinolytics

While lumbrokinase, nattokinase and serrapeptase are all effective thrombolytics, lumbrokinase is by far the most potent, which is why it’s my personal favorite. Lumbrokinase is 30 times more potent than nattokinase and 300 times more potent than serrapeptase.17,18,19

This means you need much higher doses if you’re taking nattokinase or serrapeptase, compared to lumbrokinase. That said, as just mentioned, if you intend to take a fibrinolytic enzyme daily, I recommend alternating them to prevent a sensitivity or allergy from developing. Also remember that they must be taken on an empty stomach.

Aside from potency, each enzyme also has its own set of benefits that might make one preferable over another:

1.Lumbrokinase — A highly effective antithrombotic agent that reduces blood viscosity and platelet aggregation20 while also degrading fibrin, which is a key factor in clot formation.

I recommend that everyone keep some high-quality lumbrokinase in your emergency kit. A while back I developed a significant bruise from a weight training injury. I took a high dose of lumbrokinase for a week, which cleared it up.

I also took lumbrokinase after being stung by three wasps on my forehead right before bed. The stings swelled to nearly the size of half a tennis ball. Wasp venom contains proteins that fibrinolytic enzymes can break down, so I took half a dozen pills and went to sleep.

The next morning, the swelling was nearly gone. If you are going to try this, the sooner you take it after you’re stung, the better it will likely work as it denatures the venom proteins before they inflict their damage.

2.Serrapeptase — Research has shown serrapeptase can help patients with chronic airway disease, lessening the viscosity of sputum and reducing coughing.21 Serrapeptase also breaks down fibrin and helps dissolve dead or damaged tissue without harming healthy tissue.22

3.Nattokinase — Nattokinase has been shown to break down blood clots and reduce the risk of serious clotting23 by dissolving excess fibrin in your blood vessels,24 improving circulation and decreasing blood viscosity.

Aspirin Has Benefits Similar to Fasting

I have long been a fan of fasting for many reasons, but primarily because it has been known to lower biomarkers of inflammation as well as increase autophagy. Interestingly, there was a study done that suggests that aspirin also does precisely this. The study was in mice and used 8 mg/kg which is the equivalent of about two 5 grain (325 mg) tablets a day.25

The study showed that aspirin, or its active metabolite salicylate, caused autophagy by inhibiting the acetyltransferase activity of EP300 which is a specific gene, also known as p300, which codes for proteins that regulate the activity of many genes in tissues throughout your body. It plays an essential role in controlling cell growth and division, prompting cells to mature and take on specialized functions.

Purchasing Guidelines for Aspirin

Getting back to aspirin, if you do decide to use aspirin, be sure to avoid coated extended-release aspirin. It’s not recommended due to the additives they put in it. Immediate-release aspirin is the preferred version and can be found on Amazon.

Look carefully at the list of inactive ingredients. The only one should be corn starch. I looked long and hard and found one that meets all those criteria. The recommended dose is one 325 milligram tablet per day with your largest meal.

Earlier this year I became convinced of the prophylactic value of aspirin, and I now take 325 mg per day. But I use a version that is not a tablet and is 99% pure USP aspirin. I find its prometabolic, antilipolytic, anti-inflammatory, anticortisol, and anti-estrogen effects very appealing, and its safety is well-established.

It is important to understand that there was a massive discrediting propaganda campaign hurled at it by Big Pharma when it came out with its panoply of expensive and dangerous non-steroidal anti-inflammatories (NSAIDs) fifty years ago. Many may not recall that I was the first person on the internet to warn the dangers of one of these NSAIDs, Vioxx, a year before it was released into the market and killed around 100,000 people.

If you are sensitive to aspirin, it would be best to use a salicylic acid or willow bark supplement. When you consume aspirin, the acetylsalicylic acid is metabolized in your body into salicylic acid, which is the compound responsible for the anti-inflammatory, pain-relieving and antithrombotic effects of aspirin. This can be found in willow bark.

To learn more about the risks and benefits of aspirin, and how it compares to fibrinolytic enzymes, see “Daily Aspirin — Healthy or Harmful?

+ Sources and References

Systemic Comparisons Between Lyme Disease and Post-Treatment Lyme Disease Syndrome in the U.S. With Administrative Claims Data

https://www.thelancet.com/journals/ebiom/article/PIIS2352-3964(23)00089-0/fulltext

Systematic comparisons between Lyme disease and post-treatment Lyme disease syndrome in the U.S. with administrative claims data

, , , , ,
Open Access
Published: March 21, 2023

Summary

Background
Post-treatment Lyme disease syndrome (PTLDS) is used to describe Lyme disease patients who have the infection cleared by antibiotic but then experienced persisting symptoms of pain, fatigue, or cognitive impairment. Currently, little is known about the cause or epidemiology of PTLDS.
Methods
We conducted a data-driven study with a large nationwide administrative dataset, which consists of more than 98 billion billing and 1.4 billion prescription records between 2008 and 2016, to identify unique aspects of PTLDS that could have diagnostic and etiologic values. We defined PTLDS based on its symptomatology and compared the demographic, longitudinal changes of comorbidity, and antibiotic prescriptions between patients who have Lyme with absence of prolonged symptoms (APS) and PTLDS.
Findings
The age and temporal distributions were similar between Lyme APS and PTLDS. The PTLDS-to-Lyme APS case ratio was 3.42%. The co-occurrence of 3 out of 19 chronic conditions were significantly higher in PTLDS versus Lyme APS—odds ratio and 95% CI for anemia, hyperlipidemia, and osteoarthrosis were 1.46 (1.11–1.92), 1.39 (1.15–1.68), and 1.62 (1.23–2.12) respectively. We did not find significant differences between PTLDS and Lyme APS for the number of types of antibiotics prescribed (incidence rate ratio = 1.009, p = 0.90) and for the prescription of each of the five antibiotics (FDR adjusted p values 0.72–0.95).
Interpretation
PTLDS cases have more codes corresponding to anemia, hyperlipidemia, and osteoarthrosis compared to Lyme APS. Our finding of hyperlipidemia is consistent with a dysregulation of fat metabolism reported by other researchers, and further investigation should be conducted to understand the potential biological relationship between the two.
Funding
Steven & Alexandra Cohen Foundation, Global Lyme Alliance, and the Pazala Foundation; National Institutes of Health R01ES032470.
________________
**Comment**
The first noticeable issue here is it is nearly impossible to determine if the infection is completely cleared by medications.  This is an ongoing problem.  There is no way to test to determine if the organism(s) are completely cleared, because they are typically not found in the blood – and worthless blood testing is what is used for Lyme/MSIDS.  So, this is a major flaw with the study.
And while numerous things can cause pain, fatigue, and cognitive issues – including treatment itself, it is the experience of this patient and many that I work with that retreatment will often either clear or improve all of these symptoms.  Sometimes it depends upon finding the right drug.  Sometimes it depends upon the right dosage.  And, sometimes it depends upon the length of treatment or all three or anything in between.  Nobody’s the same and everyone seems to respond differently.  This is another ongoing problem.  MSM wants to stuff everyone into a “one size fits all” box, but this is Pandora’s Box.
And while dysregulation of fat metabolism can be improved through diet and other treatments, anemia screams Babesia and osteoarthritis screams Lyme – both of which are typically not going to improve on their own without specific pathogen consideration and subsequent antimicrobial treatment.  Nuance in treating this is what is missing in MSM – which hasn’t changed in 40 years , which is why getting to a Lyme literate doctor is your best recourse.

California’s First CDC-Confirmed Case of Borrelia Miyamotoi

https://www.lymedisease.org/californias-first-cdc-confirmed-case-of-borrelia-miyamotoi/

California’s first CDC-confirmed case of Borrelia miyamotoi

By Lonnie Marcum

May 4, 2023

A recent case reminds us that Lyme disease isn’t the only tick-borne disease we need to worry about.

Last year, the CDC confirmed California’s first known case of Borrelia miyamotoi—a tick-borne pathogen that causes a relapsing-fever illness in humans.

This discovery highlights the need for increased awareness and surveillance of emerging tick-borne illnesses across the United States.

In this case, a man from Marin County, California, sought care at a neurology clinic in San Francisco. His symptoms included recurring fever, night sweats, mild vision changes and nausea. The fevers typically lasted one day and would recur every 10-14 days. At the time, he was also undergoing monoclonal antibody therapy for multiple sclerosis.

His standard blood work was negative for fungi, Lyme disease, brucellosis and leptospirosis. Chest x-rays and abdominal CT scans were negative as well.

The only notable blood findings were a positive antigen for Epstein-Barr virus, a low platelet count (thrombocytopenia), an elevated C-reactive protein (an inflammatory marker), and an elevated procalcitonin—a biomarker that is released in response to bacterial infections.

Specialty lab testing

Considering the patient’s immunocompromised status and continued relapsing fevers, his blood was sent to a specialty lab for next-generation DNA sequencing. The specialty lab, Karius,  says it can identify over 1000 clinically relevant pathogens including bacteria, DNA viruses, fungi, and parasites from a single blood sample.

The DNA test results came back positive for Borrelia miyamotoi and were sent to the CDC for confirmation. The CDC confirmed the patient’s blood was positive for Borrelia miyamotoi and 100% identical to an isolate that had been previously collected from an Ixodes pacificus tick in Marin County. This indicates the patient acquired the infection in California.

Borrelia miyamotoi, first identified in Japan in 1995, is considered an emerging infectious disease in Asia, Europe and the United States.

A recent study found widespread evidence of Borrelia miyamotoi in human blood samples of people living in the northeastern United States. An earlier study found evidence of tick-borne relapsing fever (TBRF) Borrelia, including Borrelia miyamotoi in the blood of 26 out of 101 samples of residents of Mendocino County, California in the 1980s.

Another study found multiple species of relapsing fever Borrelia in blood samples drawn from patients in 16 out of 24 California counties. And a 13-year-long study found Borrelia miyamotoi in ticks found in 24 out of 48 counties in California (see map below).

Borrelia miyamotoi is transmitted to humans through the bite of infected blacklegged ticks. These are the same  hardbodied ticks (Ixodes scapularis, Ixodes pacificus) that transmit Lyme disease to humans and animals. Other types of North American tick-borne relapsing fever Borrelia (B. hermsii, B. turicatae, B. parkeri), are transmitted by soft-bodied ticks.

The symptoms of Borrelia miyamotoi disease are similar to those of other tick-borne illnesses, such as Lyme disease. But standard Lyme tests will be negative, making the diagnosis challenging.

TBRF

According to the CDC, the main symptoms of TBRF are high fever, headache, muscle and joint pain. Fewer than 1 in 10 patients will develop a rash. Left untreated, the symptoms typically repeat, producing a telltale pattern of relapsing fever lasting 1-3 days, followed by 7-10 days without a fever, followed by another 1-3 days of fever.

The CDC website says: “Confirmation of a diagnosis relies on 1) the use of polymerase chain reaction (PCR) tests that detect DNA from the organism or 2) antibody-based tests. Both types of tests are under development and not widely commercially available but can be ordered from a limited number of CLIA-approved laboratories.”

Treatment for TBRF involves the use of antibiotics, such as doxycycline, amoxicillin or cefuroxime . In this case the man was given a 4-week course of doxycycline and achieved complete resolution of his symptoms. One month after completing antibiotics ,follow-up laboratory testing showed complete resolution of thrombocytopenia and normalization of inflammatory markers.

All tick-borne diseases are a significant health concern worldwide, particularly in areas where ticks are prevalent. These illnesses can present with a range of symptoms, some of which can be mysterious and difficult to diagnose.

While relapsing fever Borrelia has been detected in California before, this is the first CDC-confirmed case of Borrelia miyamotoi in California.  This case highlights the need for continued education and awareness of tick-borne diseases.

As with all tick-borne illnesses, prevention is key. To reduce the risk of tick bites, take precautions when spending time outdoors, such as pre-treating shoes and clothing with permethrin, using insect repellant on yourself, your children and your pets, and performing thorough tick checks after being outdoors.

LymeSci is written by Lonnie Marcum, a Licensed Physical Therapist and mother of a daughter with Lyme. She served two terms on a subcommittee of the federal Tick-Borne Disease Working Group. Follow her on Twitter: @LonnieRhea  Email her at: lmarcum@lymedisease.org.

Reference

Rubio LA, Kjemtrup AM, Marx GE, Cronan S, Kilonzo C, Saunders MEM, et al. Borrelia miyamotoi infection in immunocompromised man, California, USA, 2021. Emerg Infect Dis. 2023 May https://doi.org/10.3201/eid2905.221638 DOI: 10.3201/eid2905.221638

Padgett K, Bonilla D, Kjemtrup A, Vilcins I-M, Yoshimizu MH, Hui L, et al. (2014) Large Scale Spatial Risk and Comparative Prevalence of Borrelia miyamotoi and Borrelia burgdorferi Sensu Lato in Ixodes pacificus. PLoS ONE 9(10): e110853. https://doi.org/10.1371/journal.pone.0110853

Additional Resources

Stanford: Tick-borne disease risk high in SF Bay Area

Yale: Tick-borne Borrelia miyamotoi widespread in northeastern US

LYME SCI: Infected ticks in California? It’s complicated.

LYME SCI: B. miyamotoi has been in California ticks for a long time

LYME SCI: Lyme-carrying ticks in West differ from their Eastern cousins

LYME SCI: How many “negative” Lyme tests are due to B. miyamotoi?

LYME SCI: Tick infection rates as high as 31% in some coastal areas of California

BALF: New interactive maps show where citizen scientists found infected ticks

For more:

And the question begging to be asked is: how many people with B. miyamotoi are falling through the cracks?  It isn’t even reportable to the CDC yet (which notoriously undercounts all things tick-borne-related).

For more:  https://igenex.com/tick-talk/what-you-need-to-know-about-borrelia-miyamotoi/

This article points out the confusion with B. miyamotoi: 

  • many separate it from other tick-borne relapsing fevers
  • while it can cause relapsing fevers, it sometimes doesn’t
  • it appears to be the only TBRF transmitted from a hard bodied tick, unlike TBRF which is mainly transmitted from a soft bodied tick (I remain skeptical of this as ticks have repeatedly been found to transmit things they shouldn’t – just like they are found in places they shouldn’t be.)
  • symptoms often resemble Lyme disease
  • you can be infected with BOTH B. miyamotoi AND Lyme disease (as well as numerous other coinfections) which will complicate symptom presentation
  • testing for B. miyamotoi is just as abysmal as it is for Lyme/MSIDS:  https://madisonarealymesupportgroup.com/2020/03/01/study-cdcs-2-tier-lyme-testing-inaccurate-in-more-than-70-of-cases/

Long Term COVID Injection Data: Evidence of Sustained Vascular Injury & Thrombosis at 2 Years

https://petermcculloughmd.substack.com/p/long-term-covid-19-vaccine-data-evidence?

Long Term COVID-19 Vaccine Data–Evidence of Sustained Vascular Injury and Thrombosis at 2 Years

Direct Observation of Retinal Blood Vessels Reveals Anticipated Disaster

MAY 5, 2023

By Peter A. McCullough, MD, MPH

Early in 2020 I published with former US FDA physician Dr. Zhang that the SARS-CoV-2 viral Spike protein was damaging blood vessels and causing blood clotting. Our observations were this was occurring at the level at the vascular endothelium. This means capillaries would be systemically injured if exposed high concentrations of the Spike protein. Dr. Bruce Patterson has demonstrated the Spike protein is long-lasting (months to years) in the human body after both severe COVID-19 infection and vaccination. This leads us to a concern, that the vaccinated would have sustained vascular damage over the long-term. Now the first two-year data report in and the news could not be worse.  (See link for article)

https://www.nature.com/articles/s41541-023-00661-7

Risk assessment of retinal vascular occlusion after COVID-19 vaccination

Jing-Xing LiYu-Hsun WangHenry BairShu-Bai HsuConnie ChenJames Cheng-Chung Wei & Chun-Ju Lin

Abstract

Coronavirus disease 2019 (COVID-19) vaccines are associated with several ocular manifestations. Emerging evidence has been reported; however, the causality between the two is debatable. We aimed to investigate the risk of retinal vascular occlusion after COVID-19 vaccination. This retrospective cohort study used the TriNetX global network and included individuals vaccinated with COVID-19 vaccines between January 2020 and December 2022. We excluded individuals with a history of retinal vascular occlusion or those who used any systemic medication that could potentially affect blood coagulation prior to vaccination. To compare the risk of retinal vascular occlusion, we employed multivariable-adjusted Cox proportional hazards models after performing a 1:1 propensity score matching between the vaccinated and unvaccinated cohorts. Individuals with COVID-19 vaccination had a higher risk of all forms of retinal vascular occlusion in 2 years after vaccination, with an overall hazard ratio of 2.19 (95% confidence interval 2.00–2.39). The cumulative incidence of retinal vascular occlusion was significantly higher in the vaccinated cohort compared to the unvaccinated cohort, 2 years and 12 weeks after vaccination. The risk of retinal vascular occlusion significantly increased during the first 2 weeks after vaccination and persisted for 12 weeks. Additionally, individuals with first and second dose of BNT162b2 and mRNA-1273 had significantly increased risk of retinal vascular occlusion 2 years following vaccination, while no disparity was detected between brand and dose of vaccines. This large multicenter study strengthens the findings of previous cases. Retinal vascular occlusion may not be a coincidental finding after COVID-19 vaccination.

_______________

**Comment**

Not being a paid-subscriber, I could not access the study McCullough mentions; however, there have been case reports showing long post-COVID “vaccination” syndrome (LPCVS).

  • In this one, a 39 year old male with an uneventful medical history developed severe adverse reactions immediately after the third dose of Moderna.  Symptoms included brief fever, headache, flickering eyes, skin rashes, tiredness, insomnia, disorientation, dizziness (brain fog), tiredness, impaired thinking and concentration, emotional disorders, neck swelling, pulling/shaking/pulsating feeling inside the head, white light after eye closure, whole body vibration, panic attacks, pain in left ear, word finding disorders, various skin reactions, and non-specific white matter lesions in a frontotemporal distribution.
  • This retrospective analysis of clinically confirmed LPCVS states it is an “increasingly recognized disease that occurs after SARS-CoV-s vaccination and lasts for more than 4 weeks.  Important excerpt:

Although LPCVS leads to long-term disability, it is not widely recognized and not always accepted by manufacturers, health authorities, and even scientists. LPCVS should not be dismissed as a functional disorder and patients with LPCVS should be taken seriously.

  • This study asks if adverse events are being missed and then goes on to state that adverse events occurring with the COVID injections have never happened with other previously administered vaccines and are mainly vascular side effects that have occurred in the brain, vascular system of the limbs, abdomen, and heart, including CVST/CVT, VITT, DIC, DVT, PTE, CLS, AHA, ITP, SVT, cardiac arrest, HF, MI, pericarditis, and myocarditis, respectively. Ocular involvement includes uveitis, bilateral retinal detachment, central serous retinopathy, acute macular retinopathy, AAION and AZOOR, and paracentral acute middle maculopathy. The thyroid gland can also cause thyroiditis. Neurological side effects such as GBS, Bell’s palsy, stroke, and transverse myelitis have also been observed. It causes filler on the face. In addition to facial involvement, skin infections such as erythema multiforme, chilblains, and cutaneous vasculitis have also been reported. It causes autoimmune hepatitis in the liver and has caused many complications for the kidneys. Symptoms of immune rheumatologic events have also been observed in some patients. Lymphadenitis is one of the immune complications in the lymph nodes. In addition to the above, it also causes spontaneous abortion and menstrual problems in women. CVST/CVT, Cerebral venous sinus thrombosis/Cerebral venous thrombosis; VITT, Vaccine-induced immune thrombotic thrombocytopenia; DIC, Disseminated intravascular coagulation; DVT, Deep vein thrombosis; PTE, Pulmonary thromboendarterectomy; CLS, Capillary leak syndrome; AHA, Acquired hemophilia A; ITP, Immune thrombocytopenic purpura; SVT, Supraventricular tachycardia; HF, Heart failure; MI, Myocardial infarction; AAION, Arteritic anterior ischemic optic neuropathy; AZOOR, Acute zonal occult outer retinopathy; GBS, Guillain-Barré syndrome.

I think reality is beginning to come home to roost.  It’s going to be pretty hard to continue to sweep these devastating injuries and sudden deaths under the rug as they have been doing; however, until people decide to speak up and be willing to connect the dots, ‘the powers that be’ will continue to ignore what’s happening before their very eyes and pretend it doesn’t exist.

For more:

Study: Bait Boxes and Met52 Not Effective in Controlling Tick Populations

https://danielcameronmd.com/tick-control-methods-not-effective-residential-neighborhoods/

TICK CONTROL METHODS NOT EFFECTIVE IN RESIDENTIAL NEIGHBORHOODS

Mouse with tick embedded on shrub branch.

Controlling tick populations can help reduce the likelihood of individuals being bitten by an infected tick and developing a tick-borne illness, such as Lyme disease. Multiple types of tick control methods have been employed but with varying degrees of success. This study explores the effectiveness of bait boxes and the biopesticide spray Met52 in reducing tick abundance and tick encounters with humans.

In their study, “Impacts Over Time of Neighborhood-Scale Interventions to Control Ticks and Tick-Borne Disease Incidence,” Ostfeld and colleagues examined the effectiveness of tick control methods in 24 residential neighborhoods endemic for Lyme disease in New York.¹

The study, conducted over several years, assessed the impact of tick control system (TCS) bait boxes and Met52 spray on reducing tick abundance and tick encounters with people and outdoor pets. And whether these interventions led to a decrease in reported cases of tick-borne diseases.

“Rapid increases in incidence rates and geographic ranges of tick-borne diseases have stimulated efforts to reduce human exposure.”

The authors examined two interventions:

TCS Bait Boxes

TCS bait boxes attract small animals to a food source inside an enclosed device and apply the tick-killing chemical, fipronil. (Fipronil is lethal to ticks but harmless to mammals.)

Met52 Spray

Met52 spray is a biopesticide, which consists of spores of the F52 strain of the fungus Metarhizium brunneum. The solution, mixed with water, is sprayed on the ground and low-lying vegetation.

Impact varies with type of tick control intervention

“By killing ticks attached to small mammals, TCS bait boxes are expected to affect the abundance of host-seeking (questing) ticks the following year,” the authors explain.

Whereas, “Met52 targets host-seeking ticks, with impacts expected within days to weeks after deployment.”

Unfortunately, interventions were unable to control tick populations in 24 residential neighborhoods in New York over a 4-to-5-year period.

“… the lack of association between reduced abundance of host-seeking nymphal blacklegged ticks in residential areas receiving acaricidal treatments and the incidence of tick-borne diseases in those areas … suggests that tick control for disease reduction needs new approaches.”

STUDY FINDINGS:

  • The study found that in neighborhoods with active bait boxes, questing blacklegged ticks and ticks attached to small mammals were reduced by approximately 50%.
  • These interventions “significantly reduced owner-reported cases of tick-borne diseases in outdoor pets,” the authors point out.
  • However, “neither intervention (nor both combined) was associated with reductions in either human encounters with ticks or self-reported cases of tick-borne disease.”
  • “In neighborhoods with active TCS bait boxes, populations of blacklegged ticks (Ixodes scapularis) were not reduced over time in any of the three habitat types tested (forest, lawn, shrub/garden).”
  • “There was no significant effect of Met52 on tick abundance overall…”